Andrew F Voter
Overview
Explore the profile of Andrew F Voter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Koo A, Jia W, Kim S, Scalf M, Boos C, Chen Y, et al.
bioRxiv
. 2024 Nov;
PMID: 39553946
RIF1 (RAP1 interacting factor) fulfills diverse roles in DNA double-strand break repair, DNA replication, and nuclear organization. RIF1 is expressed as two splice variants, RIF1-Long (RIF1-L) and RIF1-Short (RIF1-S), from...
3.
Murthy V, Voter A, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al.
J Nucl Med
. 2024 Sep;
65(11):1740-1744.
PMID: 39327018
The phase 3 VISION trial demonstrated that [Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]-positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based...
4.
Cueny R, Voter A, McKenzie A, Morgenstern M, Myers K, Place M, et al.
bioRxiv
. 2024 Aug;
PMID: 39185182
G-quadruplex (G4) structures can form in guanine-rich DNA or RNA and have been found to modulate cellular processes including replication, transcription, and translation. Many studies on the cellular roles of...
5.
Voter A, Gafita A, Werner R, De Jesus-Acosta A, Rowe S, Solnes L
J Nucl Med
. 2024 Jul;
65(9):1423-1426.
PMID: 38991754
Lu-DOTATATE is an effective second-line treatment for metastatic or nonresectable neuroendocrine tumors. This treatment can result in hematologic severe adverse reactions (SARs). Preemptive identification of patients at risk of SARs...
6.
Oldan J, Almaguel F, Voter A, Duran A, Gafita A, Pomper M, et al.
Cancer J
. 2024 May;
30(3):176-184.
PMID: 38753752
Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume metastatic disease, was limited....
7.
Li Y, Imami M, Zhao L, Amindarolzarbi A, Mena E, Leal J, et al.
J Imaging Inform Med
. 2024 Apr;
37(5):2206-2215.
PMID: 38587770
Uptake segmentation and classification on PSMA PET/CT are important for automating whole-body tumor burden determinations. We developed and evaluated an automated deep learning (DL)-based framework that segments and classifies uptake...
8.
Wang F, Liu C, Vidal I, Mana-Ay M, Voter A, Solnes L, et al.
J Nucl Med
. 2023 Dec;
65(1):87-93.
PMID: 38050147
This study aimed to assess the accuracy of intraprostatic tumor volume measurements on prostate-specific membrane antigen-targeted F-DCFPyL PET/CT made with various segmentation methods. An accurate understanding of tumor volumes versus...
9.
Voter A, Werner R, Savas H, Gafita A, Ross A, Gorin M, et al.
Semin Nucl Med
. 2023 Nov;
54(1):119-131.
PMID: 37980186
Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies....
10.
Alnammi M, Liu S, Ericksen S, Ananiev G, Voter A, Guo S, et al.
J Chem Inf Model
. 2023 Aug;
63(17):5513-5528.
PMID: 37625010
Traditional small-molecule drug discovery is a time-consuming and costly endeavor. High-throughput chemical screening can only assess a tiny fraction of drug-like chemical space. The strong predictive power of modern machine-learning...